Redirecting traffic using the XPO1 police

Blood

Volumn 122, Issue 17, 2013, Pages 2926-2928

  Abraham, Sheela A ^a   Holyoake, Tessa L ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILEUKEMIC AGENT; BCR ABL PROTEIN; EXPORTIN 1; KPT 330; NUCLEOCYTOPLASMIC TRANSPORT PROTEIN; PHOSPHOPROTEIN PHOSPHATASE 2A; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; BLAST CELL CRISIS; CHRONIC MYELOID LEUKEMIA; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN FUNCTION; REVIEW;

EID: 84888210057     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-523670     Document Type: Review

References (8)

1. Walker CJ, Oaks JJ, Santhanam R, et al. Preclinical and clinical efficacy of XPO1/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph1 leukemias. Blood. 2013;122(17):3034-3044.
2. Tai YT, Landesman Y, Acharya C, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications [published online ahead of print April 16, 2013]. Leukemia.
3. Etchin J, Sanda T, Mansour MR, et al. KPT-330 inhibitor of CRM1 (XPO1)-mediated nuclear export has selective anti-leukaemic activity in preclinical models of T-cell acute lymphoblastic leukaemia and acute myeloid leukaemia. Br J Haematol. 2013;161(1):117-127.
4. Lapalombella R, Sun Q, Williams K, et al. Selective inhibitors of nuclear export show that CRM1/XPO1 is a target in chronic lymphocytic leukemia. Blood. 2012;120(23):4621-4634.
5. Turner JG, Dawson J, Sullivan DM. Nuclear export of proteins and drug resistance in cancer. Biochem Pharmacol. 2012;83(8):1021-1032.
6. Vigneri P, Wang JY. Induction of apoptosis in chronic myelogenous leukemia cells through nuclear entrapment of BCR-ABL tyrosine kinase. Nat Med. 2001;7(2):228-234.
7. Allan EK, Hamilton A, Hatziieremia S, et al. Nuclear entrapment of BCR-ABL by combining imatinib mesylate with leptomycin B does not eliminate CD341 chronic myeloid leukaemia cells. Leukemia. 2009;23(5):1006-1008.
8. Goldstein I, Madar S, Rotter V. Cancer research, a field on the verge of a paradigm shift? Trends Mol Med. 2012;18(6):299-303.